Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone.
Peter M. Lynch, MPH
Advertisement
Articles by Peter M. Lynch, MPH
A retrospective claims analysis of managed care enrollees with type 2 diabetes mellitus showed that insulin pump therapy reduced antidiabetic drug and healthcare resource use.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden
3
Pediatric Cancer Carries Greater Financial Toxicity Than Adult Disease, Driving Calls for Systemic Change
4
Integrated VA Care Linked to Equitable Cancer Survival for Black Veterans
5